Understanding and Restoring Dopaminergic Function in Fibromyalgia Patients

NCT ID: NCT04451564

Last Updated: 2021-01-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

80 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-03-31

Study Completion Date

2024-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Fibromyalgia (FM) is a very prevalent and debilitating chronic pain disorder that is difficult to treat. Mindfulness-based techniques are regarded as a very promising approach for the treatment of chronic pain and in particular FM. The Mindfulness-Oriented Recovery Enhancement (MORE) intervention, a mindfulness-based group intervention, has shown beneficial effects in opioid-treated chronic pain patients, including reduced pain severity, functional interference, and opioid dosing, by restoring neurophysiological and behavioral responses to reward. First evidence for a hypodopaminergic state and impaired reward processing in FM have been reported. However, little is known about its impact on dopamine (DA) function and in particular with regard to DA responses to monetary reward in FM. The aim of the present study protocol is to evaluate if MORE is able to restore the DA function in FM patients, in particular with regard to the DA responses to reward, and to reduce pain and mood complaints in FM.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

the present study is a multi-center randomized controlled trial (RCT) with 3 time points: before the intervention, after completion of the intervention and 3-months after completion of the intervention. Eighty FM patients will be randomly assigned to either the MORE intervention (N=40) or to a wait-list control group (N=40). Additionally a comparison group of healthy women (N=20) will be enrolled. The MORE intervention consists of eight 2-hour long group sessions administered weekly over a period of 8 weeks. Before and after the intervention, FM participants will undergo \[18F\] DOPA Positron Emission Tomography (PET) and functional magnetic resonance (MR) imaging while performing a monetary reward task. The primary outcome will be endogeneous DA changes measured with \[18F\] DOPA PET at baseline, after the intervention (after 8 weeks for control group), and at 3 months' follow-up. Secondary outcomes will be (1) clinical pain measures and FM symptoms using standardized clinical scales 2) functional brain changes 3) measures of negative and positive affect, stress and reward experience in daily life using the Experience Sampling method (ESM) 4) biological measures of stress including cortisol and alpha-amylase.

Design: If the findings of this study confirm the effectiveness of MORE in restoring DA function, reducing pain and improving mood symptoms, MORE can be judged to be a promising means to improve quality of life in FM patients. The findings of this trial may inform health care providers about the potential use of the MORE intervention as a possible non-pharmacological intervention for FM.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Fibromyalgia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

MORE Mindfulness oriented recovery enhancement group

MORE Mindfulness oriented recovery enhancement group

Group Type EXPERIMENTAL

Mindfulness oriented recovery enhancement

Intervention Type BEHAVIORAL

8- week psychological program based on mindfulness techniques

Control

wait-list

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Mindfulness oriented recovery enhancement

8- week psychological program based on mindfulness techniques

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Fibromyalgia syndrome
* no psychiatric disorders
* right handed
* older than 18 years,

Exclusion Criteria

* male sex
* history of neurological disorders
* left handed
* psychiatric disorders
* current substance or tobacco abuse
* current and past substance dependence
* schizophrenia spectrum disorder
* any other form of chronic pain apart from Fibromyalgia
Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Lausanne

OTHER

Sponsor Role collaborator

University of Zurich

OTHER

Sponsor Role collaborator

University of Utah

OTHER

Sponsor Role collaborator

University of Fribourg

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Chantal o Martin Sölch, PhD

Role: PRINCIPAL_INVESTIGATOR

University of Fribourg

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Fribourg

Fribourg, , Switzerland

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Switzerland

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

katharina Ledermann

Role: CONTACT

+41765330316

Maya Burckhard

Role: CONTACT

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Katharina ledermann

Role: primary

+41765330316 ext. +41765330316

Chantal martin Sölch

Role: backup

References

Explore related publications, articles, or registry entries linked to this study.

Ledermann K, von Kanel R, Berna C, Sprott H, Burckhardt M, Jenewein J, Garland EL, Martin-Solch C. Understanding and restoring dopaminergic function in fibromyalgia patients using a mindfulness-based psychological intervention: a [18F]-DOPA PET study. Study protocol for the FIBRODOPA study-a randomized controlled trial. Trials. 2021 Dec 1;22(1):864. doi: 10.1186/s13063-021-05798-1.

Reference Type DERIVED
PMID: 35078536 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

FIBRODOPA TRIAL

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Repetitive Thinking in Fibromyalgia
NCT03964285 COMPLETED NA
Pain Management Techniques for Fibromyalgia
NCT00086060 COMPLETED PHASE1/PHASE2
Randomized Controlled Trial of CES for Fibromyalgia
NCT04115033 ACTIVE_NOT_RECRUITING NA
Behavioral Treatment of Fibromyalgia
NCT00000398 COMPLETED PHASE2